- Home
- SLS vs LCTX Comparison
SLS vs LCTX Comparison
Compare SLS & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLS
- LCTX
- Stock Information
- Founded
- SLS 2012
- LCTX 1990
- Country
- SLS United States
- LCTX United States
- Employees
- SLS N/A
- LCTX N/A
- Industry
- SLS Biotechnology: Pharmaceutical Preparations
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLS Health Care
- LCTX Health Care
- Exchange
- SLS Nasdaq
- LCTX Nasdaq
- Market Cap
- SLS 89.6M
- LCTX 95.2M
- IPO Year
- SLS N/A
- LCTX N/A
- Fundamental
- Price
- SLS $1.40
- LCTX $0.49
- Analyst Decision
- SLS
- LCTX Strong Buy
- Analyst Count
- SLS 0
- LCTX 5
- Target Price
- SLS N/A
- LCTX $4.20
- AVG Volume (30 Days)
- SLS 1.3M
- LCTX 1.3M
- Earning Date
- SLS 05-13-2025
- LCTX 05-08-2025
- Dividend Yield
- SLS N/A
- LCTX N/A
- EPS Growth
- SLS N/A
- LCTX N/A
- EPS
- SLS N/A
- LCTX N/A
- Revenue
- SLS N/A
- LCTX $9,499,000.00
- Revenue This Year
- SLS N/A
- LCTX N/A
- Revenue Next Year
- SLS N/A
- LCTX $232.66
- P/E Ratio
- SLS N/A
- LCTX N/A
- Revenue Growth
- SLS N/A
- LCTX 6.19
- 52 Week Low
- SLS $0.77
- LCTX $0.37
- 52 Week High
- SLS $1.84
- LCTX $1.40
- Technical
- Relative Strength Index (RSI)
- SLS 72.02
- LCTX 54.53
- Support Level
- SLS $1.29
- LCTX $0.37
- Resistance Level
- SLS $1.38
- LCTX $0.44
- Average True Range (ATR)
- SLS 0.09
- LCTX 0.04
- MACD
- SLS 0.03
- LCTX 0.01
- Stochastic Oscillator
- SLS 86.54
- LCTX 81.99
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.